CTI BioPharma (NASDAQ: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. Pacritinib is also being investigated in acute graft versus host disease (GvHD) in an ongoing investigator-sponsored Phase 1/2 study. We are headquartered in Seattle, Washington.
Location: United States, Washington, Seattle
Employees: 201-500
Founded date: 1992
Investors 3
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Hercules C... | htgc.com |
| - | Ignite 500 | ignite500.... |
Mentions in press and media 29
| Date | Title | Description |
| 10.06.2024 | Sobi to present new data across its haematology portfolio at the 2024 EHA congress | Sobi to present new data across its haematology portfolio at the 2024 EHA congress Mon, Jun 10, 2024 12:15 CET Report this content Sobi® will present data at the EHA (European Haematology Association) hybrid congress, taking place in Madrid... |
| 20.11.2023 | Sobi to present new data at ASH 2023 Annual Meeting | Sobi to present new data at ASH 2023 Annual Meeting Mon, Nov 20, 2023 08:00 CET Report this content Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of ... |
| 25.05.2023 | Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp. | Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp. Thu, May 25, 2023 13:30 CET Report this content NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTI... |
| 10.05.2023 | Sobi to Acquire CTI BioPharma, for Approx. $1.7 Billion | Swedish Orphan Biovitrum AB (STO: SOBI) (“Sobi”), a global healthcare leader in hematology, immunology and specialty care, is to acquire CTI BioPharma (Nasdaq: CTIC), a Seattle, WA-based commercial biopharmaceutical company focused on the d... |
| 10.05.2023 | Sobi to acquire CTI BioPharma Corp. enhancing Sobi’s position in rare haematology | Sobi to acquire CTI BioPharma Corp. enhancing Sobi’s position in rare haematology Wed, May 10, 2023 07:00 CET Report this content NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO ... |
| 08.09.2021 | CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 26.08.2021 | CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 24.08.2021 | CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors | |
| 26.07.2021 | CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 09.07.2021 | CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Show more